Trial · NCT02484339
Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
NCT02484339, Phase 2, Unknown, University Hospital Freiburg
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT). Trials, record NCT02484339. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02484339
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
- NCT number
- NCT02484339
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 274 participants, estimated
- Lead sponsor
- University Hospital Freiburg
- Conditions
- Prostate Carcinoma
- Interventions
- Radium-223 dichloride, Conventional or high dose radiotherapy
- First posted
- 2015-06-29
- Last updated
- 2016-04-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to radiological progression free survival (PFS) rate | randomization to radiological progression | measured every 3 month by Bone Scan and MRI or CT until Follow up 7 (month 24) and after that in long term follow up every 6 month |
| Secondary | Time to local progression in any of the EBRT treated bone metastases of conventional radiotherapy (CRT) vs. High-dose image-based conformal radiotherapy (HIRT) treatment techniques | Time to local progression in any of the EBRT treated bone metastases | measured every 3 month by Bone Scan, Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) until month 24 after that in long term follow up every 6 month with open end |
| Secondary | Overall survival | randomization to death | Follow up every 3 month until month 24 and after that in long term follow up every 6 month |
| Secondary | Time to distant bone metastasis progression outside the RT target volumes | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | Follow up every 3 month until month 24 and than in long term follow up every 6 month measured by increasing of PSA, CT/MRI |
| Secondary | Time to Skeletal Related Event (SRE) | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | measured every 3 month by Bone Scan, Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) until month 24 and than in long term follow up every 6 month with open end |
| Secondary | Pain control | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | measured every 3 month by the Brief Pain Inventory Short Form (BPI-SF), the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C15-PAL and the EORTC QLQ- Bone Metastases (BM) 22 until month 24 and than in long term follow up every 6 month |
| Secondary | Disease Control Rate (DCR); Response rates according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | Follow up every 3 month until month 24 measured by RECIST criteria and than in long term follow up every 6 month |
| Secondary | PSA response, time to PSA response and time to PSA normalization | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | Follow up every 3 month until month 24 and after that long term follow up every 6 month measured by PSA level |
| Secondary | Bone alkaline phosphatase (ALP) response, time to bone ALP response | Screening to FU 7 (after 24 months) and than in long term follow up every 6 month | Follow up every 3 month until month 24 and than long term follow up every 6 month measured by blood level |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02484339
GET https://conductscience.org/api/trials/v1/NCT02484339/registered